Skip to search formSkip to main contentSkip to account menu

TG02

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Centimeter-Level Orbit Determination for TG02 Spacelab Using Onboard GNSS Data
Tiangong-2, the second Chinese manned spacecraft, was launched into low Earth orbit on 15 September 2016. The dual-frequency… 
2017
2017
EXTH-67. TG02, A BRAIN-PENETRANT MULTI-CDK INHIBITOR, POTENTLY SUPPRESSES MYC-DRIVEN GLIOBLASTOMA
2016
2016
Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
Direct co-operation between sensitiser molecules BAD and NOXA in mediating apoptosis suggests that therapeutic agents which… 
2014
2014
Abstract 4536: ABT-737 and ABT-199 complement the multikinase inhibitor TG02 to induce apoptosis in acute myeloid leukemia cells
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA TG02 is a novel multikinase inhibitor currently in Phase 1… 
2013
2013
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma
ABSTRACT Carfilzomib (Kyprolis®), a second generation proteasome inhibitor, is FDA approved for single-agent use among relapsed… 
2012
2012
The multi‐kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells
The novel multi‐kinase inhibitor TG02 has selectivity against cell cycle and transcriptional cyclin dependent kinases (CDKs) as… 
2012
2012
Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
SB1317 (TG02) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. To evaluate full potential of this development candidate… 
2012
2012
Abstract 2830: Multikinase inhibition by TG02 is therapeutically effective in two forms of breast cancer
Breast cancer (BC) is a heterogeneous disease in which several distinct genetic and histopathological types have been defined… 
2010
2010
Antimyeloma Action of the Multikinase Inhibitor TG02
Abstract 4062 Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable, despite recent… 
2010
2010
Abstract 2542: TG02, a novel multi-kinase inhibitor with potent anti-leukemic activity
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Kinase inhibitors have found applications in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)